Do Institutional Investors Love Immune Design Corp. (NASDAQ:IMDZ)?

April 22, 2018 - By Migdalia James

Sentiment for Immune Design Corp. (NASDAQ:IMDZ)

Immune Design Corp. (NASDAQ:IMDZ) institutional sentiment increased to 1.92 in 2017 Q4. Its up 0.65, from 1.27 in 2017Q3. The ratio is positive, as 50 institutional investors increased or started new stock positions, while 26 decreased and sold stakes in Immune Design Corp.. The institutional investors in our partner’s database now hold: 23.09 million shares, up from 11.88 million shares in 2017Q3. Also, the number of institutional investors holding Immune Design Corp. in their top 10 stock positions decreased from 3 to 1 for a decrease of 2. Sold All: 14 Reduced: 12 Increased: 26 New Position: 24.

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company has market cap of $168.44 million. The firm primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. It currently has negative earnings. The Company’s lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

The stock decreased 4.11% or $0.15 during the last trading session, reaching $3.5. About 186,478 shares traded. Immune Design Corp. (NASDAQ:IMDZ) has declined 53.26% since April 22, 2017 and is downtrending. It has underperformed by 64.81% the S&P500.

Analysts await Immune Design Corp. (NASDAQ:IMDZ) to report earnings on May, 3. They expect $-0.29 EPS, up 42.00 % or $0.21 from last year’s $-0.5 per share. After $-0.29 actual EPS reported by Immune Design Corp. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Proquest Associates Iv Llc holds 6.4% of its portfolio in Immune Design Corp. for 1.24 million shares. Ecor1 Capital Llc owns 3.56 million shares or 1.56% of their US portfolio. Moreover, Abingworth Llp has 1% invested in the company for 352,300 shares. The Massachusetts-based Bain Capital Public Equity Management Llc has invested 0.93% in the stock. Bvf Inc Il, a California-based fund reported 1.47 million shares.

Since January 1, 0001, it had 2 insider purchases, and 5 insider sales for $21.92 million activity.

Immune Design Corp. (NASDAQ:IMDZ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: